Catabasis Pharmaceuticals
| Region | Nordamerika |
| ISIN | US14875P2065 |
| Sektor | Biotechnologie |
| Website | https://www.catabasis.com/ |
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. Our global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com or www.twitter.com/catabasispharma.
| Titel | Autor | Datum |
|---|---|---|
|
Der Tenbagger-Kandidat für 2020!
|
sharedeals | vor ungefähr 6 Jahren |
|
Der heißeste Buyout-Kandidat des Jahres!
2 Kommentare |
sharedeals | translation missing: de.datetime.time_ago_in_words.almost_x_years |
| Titel | Datum |
|---|---|
| MISC Clinches 10 Year Charter For New LCO2 Carrier, First CCS Contract | vor 12 Tagen |
| MISC consortium wins long-term liquefied carbon dioxide carrier charter | vor 12 Tagen |
| Stock Picks: Leong Hup, IGB REIT, MISC And E&O | vor 15 Tagen |
| ABS Approves MISC and China Offshore's Ammonia FPSO Design | vor ungefähr 2 Monaten |
| MISC Berhad and China Offshore secure ABS approval in principle for ammonia FPSO concept | vor ungefähr 2 Monaten |
| Diese Aktien könnten Dich auch interessieren | |
|---|---|
| Cannabis Wheaton Income (2 Artikel) | |
| BYD Company (1 Artikel) | |
| CBLT (1 Artikel) | |
| Celgene (1 Artikel) | |
| Alle anzeigen | |